While the cure for Alzheimer’s disease (AD) remains elusive, new treatments that may slow disease progression have been making a big splash in the press lately, namely aducanumab (Aduhelm) and lecanemab (Leqembi). These monoclonal antibody drugs are also notable for having received Food and Drug Administration (FDA) approvals. However, it’s …
Read More